Diabetes and kidney transplantation: Past, present, and future

Current Diabetes Reports

Volumn 12, Issue 5, 2012, Pages 597-603

  Guerra, Giselle ^a   Ilahe, Amna ^a   Ciancio, Gaetano ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Diabetic nephropathy; Graft survival; Kidney transplantation; New onset diabetes after transplantation; Patient survival

Indexed keywords

ALEMTUZUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; BELATACEPT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DACLIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GRAFT SURVIVAL; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KETOACIDOSIS; KIDNEY ALLOGRAFT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; NEW ONSET DIABETES; NEW ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; PROTEIN EXPRESSION; RECIPIENT; RENAL REPLACEMENT THERAPY; SIDE EFFECT; SURVIVAL RATE; WOUND DEHISCENCE; WOUND INFECTION;

DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY TRANSPLANTATION;

EID: 84870829900     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0306-3     Document Type: Article

References (96)

1. National Institute of Health (NIH), (NIDDK): 2010 Annual Data Report: Atlas of end stage renal disease in the United States. In, National Institute of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2010
2. Coressh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease. JAMA. 2007;298:2038-47
3. Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end stage renal disease: 25 year follow-up. Arch Intern Med. 2009;169:342
4. Bash LD, Astor BC, Coresh J. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2010;55:31-41
5. Welsh RC, Cockfield SM, Campbell P, et al. Cardiovascular assessment of diabetic end stage renal disease patients before renal transplantation. Transplantation. 2011;9:213-8
6. Wolfe RA, Ashby VB, Milford EL, Ojo AO, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. NEJM. 1999;341:1725-30
7. Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol. 2001;12:1293-6 (Pubitemid 32472644)
8. United Network for Organ Sharing. 2012 wait-list for kidney transplantation from organ procurement and transplantation network (OPTN) data, May, 2012
9. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002;74:1377-81 (Pubitemid 35379540)
10. Son YK, Oh JS, Kim SM, et al. Clinical outcome of preemptive kidney transplantation in patients with diabetes mellitus. Transplant Proc. 2010;42:3497-502
11. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178-85 (Pubitemid 36323115)
12. Ballard DJ, Humphrey LL, Melton III LJ, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population based in Rochester, Minnesota. Diabetes. 1988;37:405-12 (Pubitemid 18096376)
13. Poulsen PL, HansenKW,Mogensen CE. Ambulatory blood pressure in the transition from normo to microalbuminuria. A longitudinal study in IDDM patients. Diabetes. 1994;43:1248-53 (Pubitemid 24361192)
14. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86
15. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62 (Pubitemid 23335891)
16. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345:861-9
17. Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation. 2000;70: SS41
18. Foley RN, Murray AM, Li S, Herzog CA, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489-95 (Pubitemid 41725146)
19. Balasubramaniam K, Viswanathan G, Marshall S, et al. Increased atherotherombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012;2012:1-18
20. Libby O, Ridker M, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43 (Pubitemid 34212626)
21. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-81 (Pubitemid 34517204)
22. Stegenga ME, van der Crabben SN, Dessing MD, et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production, and neutrophil function in humans. Diabetic Med. 2008;25:157-64 (Pubitemid 351293406)
23. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostatsis, and thrombosis. Thromb Haemaost. 2008;99:995-1000
24. Mutner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745-53 (Pubitemid 34183941)
25. Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006;17:900-7
26. Schnuell P, Lorenze D, Trede M, et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol. 1998;9:2135-41 (Pubitemid 28482164)
27. McDonald SP, Russ GR. Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991-2001. Nephrol Dial Transplant. 2002;17:2212-9 (Pubitemid 35446680)
28. Hirschl M. Renal transplantation in patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 1995;10 Suppl 7:58-60
29. Weisbauer F, Heinze G, Regele H, et al. Glucose control is associated with patient survival in diabetic patients after renal transplantation. Transplantation. 2010;89:612-9
30. Cosio FG, Hisckson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant. 2008;8:593-9 (Pubitemid 351287534)
31. Aalten J, Hoogeveen EK, Roodnat JI, et al. Associations between pre-kidney transplant risk factors and posttransplant cardiovascular events and death. Transpl Int. 2008;21:985-91
32. Kiverd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol. 2008;3:822-8
33. Shaffer D, Simpson MA, Madras PN, et al. Kidney transplantation in diabetic patients using cyclosporine. Five-year follow-up. Arch Surg. 1995;130:28-287
34. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end stage renal disease. Am J Transplant. 2004;4:1662-8 (Pubitemid 39312301)
35. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003;75:1291-5 (Pubitemid 36513036)
36. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807-18 (Pubitemid 36306835)
37. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regime: incidence, risk factors, progression, and prognosis. Transplantation. 2003;76:375-82 (Pubitemid 36928002)
38. Fl L, Samaniego M. Transplantation in diabetic kidney failure patients: modalities, outcomes, and clinical management. Semin Dial. 2010;23:198-205
39. Barbosa J, Steffers MW, Sutherland DE, et al. Effect of glycemic control on early diabetic renal lesions.A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA. 1994;272:600
40. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979-83 (Pubitemid 27446762)
41. Duijnhoven EM, Boots JM, Christiaans MH, et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12:583-8 (Pubitemid 32180028)
42. Dumler F, Kilates C. Metabolic and nutritional complications of renal transplantation. J Ren Nutr. 2007;17:97-102 (Pubitemid 46014463)
43. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335:1638-43
44. Hughes K, Kennedy B. Rapamycin paradox resolved. Cell Biol. 2012;335:1578-9
45. Kuo HT, SampaioMS, Vincent F, et al. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OTN/UNOS) Database. Am J Kidney Dis. 2010;56:1127-39
46. Parekh J, Bostrom A, Feng S. Diabetes mellitus: a risk factor for delayed graft function after deceased donor kidney transplantation. Am J Transpl. 2010;10:298-303
47. Thomas MC, Mathew TH, Russ GR, et al. Early perioperative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321-4 (Pubitemid 33026616)
48. Troppman C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation. 1995;59:962
49. Kyriakides G, Simmons R, Najarian J. Wound infections in renal transplant wounds: pathogenetic and prognostic factors. Ann Surg. 1975;182:770-5
50. Roine E, Bjork IT, Oyen O. Targeting risk factors for impaired wound healing and wound complications after kidney transplantation. Transplant Proc. 2010;42:2542-6
51. Lansang C, Ma L, Schold J, et al. The relationship between diabetes and infectious hospitalizations in renal transplant recipients. Diabetes Care. 2006;29:1659-60 (Pubitemid 44127598)
52. Abbot KC, Hypolite I, Tveit DJ, et al. Hospitalizations for fungal infections after initiation of chronic dialysis in the United States. Nephron. 2001;89:426-32 (Pubitemid 33135823)
53. Ersoy A, Ersoy C, Tekce H, et al. Diabetic ketoacidosis following development of de novo diabetes in renal transplant recipient associated with tacrolimus. Transplant Proc. 2004;36:1407-10 (Pubitemid 38902990)
54. Mazali FC, Lalli CA, Alves-Filho G, et al. Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc. 2008;40:764-6 (Pubitemid 351608687)
55. Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil, and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation. 2002;73:1100-6 (Pubitemid 34415442)
56. Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, et al. A randomized long-term trial of tacrolimus/sirolimus vs tacrolimus/mycophenolate mofetil vs cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation. 2004;77:252-8 (Pubitemid 38155755)
57. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, et al. A randomized trial of 3 renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation. 2005;80:457-65 (Pubitemid 41209412)
58. Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, et al. Randomized trial of mycophenolate mofetil vs enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: 1 year follow-up. Transplantation. 2008;86:67-74
59. Ciancio G, Gaynor JJ, Sageshima J, Guerra G, Zarak A, Roth D, et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation. 2011;92:1348-57
60. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among US wait-listed and transplant renal allograft recipients. Am J Transplant. 2003;3:590-8 (Pubitemid 36612842)
61. Luan FL, Zhang H, Schaubel DE, et al. Comparative risk of impaired glucose metabolism associated with cyclosporine vs tacrolimus in the late posttransplant period. Am J Transplant. 2008;8:1871-7
62. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systemic review of the literature. Diabetes Care. 2002;25:583-92
63. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine vs tacrolimus. Am J Transplant. 2007;7:1506-14 (Pubitemid 46776239)
64. Perez-Flores I, Sanchez Fructuoso A, Calvo EF, et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus. Transplant Proc. 2010;42:2902-4
65. Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttranplant diabetes in renal allograft recipients. Diabetes Care. 2007;30:609
66. Shah T, Kasravi A, Huang E, et al. Risk factors development of new onset diabetes mellitus after kidney transplantation. Transplantation. 2006;82:1673
67. Joss N, Staatz CE, Thomson AH, et al. Predictors of new onset diabetes after renal transplantation. Clin Transplant. 2007;21:136
68. Hjelmesaeth J, Harmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979-83 (Pubitemid 27446762)
69. Duijnhoven EM, Boots JM, Christiaans MH, et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12:583-8 (Pubitemid 32180028)
70. Menegazzo LA, Ursich MJ, Fukui RT, et al. Mechanism of the diabetogenic action of cyclosporine A. Horm Metab Res. 1998;30:663-7
71. Teutonico A, Schena FP, Paraskevas S, et al. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128-35 (Pubitemid 44743511)
72. Van Duijnhoven EM, Christiaans MHL, Boots JMM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus vs cyclosporine based immunosuppression. J Am Soc Nephrol. 2002;13:213-20 (Pubitemid 34042030)
73. th International Conference on New Trends in Immunosuppression. Austria: Salzburg; 2004. Book of Abstracts, p59
74. Pirsch JD,Miller J, Deieerhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997;63:977-83
75. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolatemofetil vs cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 2000;69:834-41 (Pubitemid 30174107)
76. Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation. 2003;75:1213-20 (Pubitemid 36513023)
77. Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation. 2000;69:875-80 (Pubitemid 30174114)
78. Rostaing L, Cantarovich D, Mourad G, et al. Steroid free immunosuppression with a combination of daclizumab, tacrolimus, and MMF is efficacious and safe: results of a large multicenter trial in renal transplantation. Am J Transplant. 2003;3 Suppl 5:312
79. Chang RW, Snowden S, Palmer A, et al. European randomized trial of dual vs triple tacrolimus based regimens for control of acute rejection in renal allograft recipients. Transpl Int. 2001;14:384-90 (Pubitemid 34000790)
80. Wlodarczyk Z, Walaszewski J, Perner F, et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus treated kidney transplant recipients. Ann Transplant. 2002;7:28-31
81. Klinger M, Vitko S, Salmela K, et al. Large prospective study evaluating steroid-free immunosuppression with tacrolimus/basiliximab and tacrolimus/MMF compared with tacrolimus/MMF/steroids in renal transplantation. Nephrol Dial Transplant. 2003;18 Suppl 4:788
82. Backman L. Post-transplant diabetes mellitus: the last 10 years with tacrolimus. Nephrol Dial Transplant. 2004;19:vi13-6
83. Van Hoof JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms posttransplant diabetes mellitus. Neprhol Dial Transplant. 2004;19 Suppl 6:vi8-vi12 (Pubitemid 40057665)
84. Araki M, Slechner S, Ismail H, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation. 2005;81:335-41
85. Tsao JP, Lian JD, Wu SW, et al. Long-term impact of pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes. World J Surg. 2011;35:2818-25
86. Davidson J, Wilkinson A, Dantal J, et al. New onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain. 19 February 2003. Transplantation. 2003;75:SS3-24
87. Becker BN, Rush SH, Dykstra DM, et al. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med. 2006;166:44-8 (Pubitemid 43063840)
88. Wiseman AC, Gralla J. Simultaneous pancreas kidney transplant vs other kidney transplant options in patients with type 2 diabetes. CJASN. 2012;7:656-64
89. WissingKM, Abramowicz D, Broeders N, et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation. 2000;70:464-72 (Pubitemid 30641501)
90. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. 1998;53:217-22 (Pubitemid 28066925)
91. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: report from the managing dyslipidemias in chronic kidney disease work group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4 Suppl 7:13-53 (Pubitemid 38436863)
92. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-290
93. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43:1071-81 (Pubitemid 38691503)
94. Rao PS, Schaubel DE, Jia X, et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis. 2007;49:294-300 (Pubitemid 46178401)
95. Ojo AO, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the Unite States Renal Data System. Transplantation. 1998;66:1651-9 (Pubitemid 29034986)
96. Su VCH, Harrison J, Rogers C, et al. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012;46:57-67.